US healthcare businesses can do more than just advance healthcare services.
These defensive businesses can also keep your income portfolio in optimal health, regardless of economic cycles.
However, not all healthcare businesses deserve a place in your income portfolio.
The key is to be discerning, selecting the most reliable, market-leading healthcare businesses with robust financial standing to support consistent dividend payouts.
For investors who seek to receive monthly dividend income with just a handful of stocks, here are a few names that could collectively pay your bills every single month.
The Portfolio That Pays You Every Month
Investors might think they need to hold dozens of stocks to receive dividends every single month.
But here’s the truth: Three healthcare stocks are all you need to construct an income portfolio that pays you every month like clockwork, based on their 2025 dividend payout dates:
- Johnson & Johnson, or J&J (NYSE: JNJ)
- Abbott Laboratories (NYSE: ABT)
- Medtronic (NYSE: MDT)
| Month | Dividend Stock |
| January | Medtronic |
| February | Abbott |
| March | J&J |
| April | Medtronic |
| May | Abbott |
| June | J&J |
| July | Medtronic |
| August | Abbott |
| September | J&J |
| October | Medtronic |
| November | Abbott |
| December | J&J |
However, dividends only last as long as the business remains strong.
Let’s check out how they hold up.
Johnson & Johnson, or J&J – The healthcare Juggernaut
J&J dominates the healthcare sector through its twin growth powerhouses: Innovative Medicine and MedTech.
The former consists of medicine in fields such as oncology, neuroscience, and more, and the latter are in areas such as cardiovascular and orthopaedics.
In the first quarter ended 29 March 2026 (1Q2026), J&J reported a revenue increase of 9.9% year on year (YoY) to US$24.1 billion, thanks to operational growth and a currency tailwind from a weakening US dollar.
However, J&J’s free cash flow (FCF) took a hit, having decreased 55.6% to US$1.5 billion from a year ago, due to higher capital expenditure and expected unfavourable changes in payment timings.
But despite the blip in FCF, J&J increased its dividends by 3.1% quarter on quarter (QoQ) to US$1.34 per share, payable on 9 June 2026.
J&J has increased its dividends for 64 consecutive years, and is likely to continue doing so, supported by a robust balance sheet of US$22.1 billion in cash and marketable securities.
Abbott Laboratories – The Healthcare Titan
With a global footprint that spans 160 countries, Abbott has four business segments: Diagnostics, medical devices, nutrition, and branded generic medicines.
The healthcare titan’s portfolio is highly diversified, ranging from non-invasive wearable devices such as the “FreeStyle Libre” continuous glucose monitor, to implantable devices such as leadless pacemakers.
This diversity of life-changing products allows Abbott to benefit from the rising secular demand for healthcare from an ageing global demography.
Abbott’s revenue climbed 7.8% YoY to US$11.16 billion in the first quarter of 2026, driven by broad-based growth and a weakening US dollar.
Unfortunately, its net earnings dropped by 18.7% to US$1.08 billion because of the acquisition of Exact Science, a cancer diagnostic company.
This acquisition is expected to benefit Abbott’s diagnostics segment. Within the segment, a key product line is the highly popular non-invasive Cologuard colorectal cancer screening toolkit.
Abbott, just like J&J, is a Dividend Aristocrat and increased its 2026 first-quarter dividend by 6.8% YoY to US$0.63 per share, maintaining its unbroken 54-year increase since 1924 – a track record that enriches income investors immensely.
Medtronic – The Healthcare Technology Giant
Medtronic has built its business around its mission of relieving pain, restoring health, and extending patients’ lives.
To this end, it segments its business into the areas of cardiovascular, neuroscience, medical surgical, and diabetes. Its products include the Hugo Robotic-Assisted Surgery (RAS) system and the Affera Sphere-9 Pulsed Field Ablation (PFA) catheter (a non-thermal alternative to tissue removal).
For the fiscal year ended 24 April 2026 (FY2026), Medtronic’s revenue grew 8.4% to US$36.36 billion, driving FCF up 4.6% to US$5.43 billion.
Crucially, Medtronic’s FY2026 FCF represented 76% of non-GAAP net earnings, showcasing the company’s highly efficient earnings-to-FCF conversion.
The Dividend Aristocrat looks set to raise its dividend for FY2027 by 1.4%, to an implied US$2.88 per share, which would mark its 49th consecutive year of dividend growth.
For income investors, this long-term value creation engine of Medtronic should not be ignored.
Get Smart: Build Your Monthly Healthcare Paycheck
All three names – J&J, Abbott, and Medtronic – are healthcare industry leaders with durable businesses and robust financial standings.
Their unbroken multi-decade track record of rewarding shareholders makes them compelling for dividend investors seeking reliable long-term dividend payouts.
Collectively, they form a powerful income-generating machine that pays you every month like clockwork, supported by their robust cash-generating businesses.
Their resilient, defensive businesses keep income coming in even through every market cycle.
Not all AI “winners” will survive this cycle.
But a few companies already have the scale, cash flow, and edge to pull ahead. We highlight what to look for in our FREE volatile market report. Download it here.
Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses!
Disclosure: Larry L. does not own shares of any companies mentioned.
